Linfeng Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Linfeng Cheng has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Dongbo Jiang
Department of Immunology, The Key Laboratory of Bio-hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), China
6 shared publications - Kun Yang
Department of Immunology, Air Force Medical University, No. 169, Changle West Road, Xi’an 710032, China
5 shared publications Shuya Yang
Department of Immunology, The Key Laboratory of Bio-hazard Damage and Prevention Medicine, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University)
4 shared publicationsYuanjie Sun
Department of Immunology, The Key Laboratory of Bio-hazard Damage and Prevention Medicine, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University)
4 shared publications- Baozeng Sun
Yingtan Detachment, Jiangxi Corps, Chinese People’s Armed Police, China
3 shared publications Fanglin Zhang
Department of Microbiology and Pathogenic Biology, School of Basic Medical Sciences, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
3 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 7994
Generation and Characterization of the Human Anti-HTNV Antibody KJJ4
Hantaan virus (HTNV) is the predominant causative agent of hemorrhagic fever with renal syndrome (HFRS) in China, yet no specific antiviral therapy is currently available. Neutralizing antibodies (NAbs) represent a promising strategy, but most existing anti-HTNV NAbs are heterologous and carry immunogenicity risks. Here, two fully human antibodies from a previously established human anti-HTNV phage display library were generated and characterized. KJJ3, a VL-VL tandem antibody derived from clone 3–12, showed weak binding to inactivated HTNV and minimal neutralizing activity (IC50 = 27.12 μg/mL). However, KJJ4, an engineered IgG4 antibody derived from clone 4–19 and carrying the S108P hinge mutation to prevent Fab-arm exchange, bound inactivated HTNV antigen and recombinant glycoprotein Gn (residues 19–371) in a dose-dependent manner, with only weak binding to Gc. Surface plasmon resonance yielded an association rate constant of 4.70 × 103 M−1s−1, a dissociation rate constant of 3.06 × 10−3 s−1, and an equilibrium dissociation constant of 650 nM for monomeric Gn19–371. In a Vero E6 focus-reduction microneutralization assay, KJJ4 neutralized HTNV in vitro with an IC50 of 2.879 μg/mL. These data establish KJJ4 as a fully human anti-HTNV antibody with experimentally defined in vitro binding and neutralizing activity, warranting further evaluation in animal models of HTNV infection.
- 8 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 7994
Open AccessGeneration and Characterization of the Human Anti-HTNV Antibody KJJ4
Hantaan virus (HTNV) is the predominant causative agent of hemorrhagic fever with renal syndrome (HFRS) in China, yet no specific antiviral therapy is currently available. Neutralizing antibodies (NAbs) represent a promising strategy, but most existing anti-HTNV NAbs are heterologous and carry immunogenicity risks. Here, two fully human antibodies from a previously established human anti-HTNV phage display library were generated and characterized. KJJ3, a VL-VL tandem antibody derived from clone 3–12, showed weak binding to inactivated HTNV and minimal neutralizing activity (IC50 = 27.12 μg/mL). However, KJJ4, an engineered IgG4 antibody derived from clone 4–19 and carrying the S108P hinge mutation to prevent Fab-arm exchange, bound inactivated HTNV antigen and recombinant glycoprotein Gn (residues 19–371) in a dose-dependent manner, with only weak binding to Gc. Surface plasmon resonance yielded an association rate constant of 4.70 × 103 M−1s−1, a dissociation rate constant of 3.06 × 10−3 s−1, and an equilibrium dissociation constant of 650 nM for monomeric Gn19–371. In a Vero E6 focus-reduction microneutralization assay, KJJ4 neutralized HTNV in vitro with an IC50 of 2.879 μg/mL. These data establish KJJ4 as a fully human anti-HTNV antibody with experimentally defined in vitro binding and neutralizing activity, warranting further evaluation in animal models of HTNV infection.
- Open Access
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1693892
Immunoreactivity of pan MHC-I epitopes on Crimean-Congo hemorrhagic fever virus glycoprotein C-terminal
Introduction: Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne pathogen causing severe hemorrhagic disease with high mortality. The viral glycoprotein Gc mediates membrane fusion and represents a key target of CD8⁺ T-cell responses. However, systematic identification and comprehensive evaluation of pan-MHC-I-restricted Gc epitopes remain limited. Methods: An integrated immunoinformatics workflow incorporating five prediction algorithms (IEDB, NetMHCpan4.1, SMMPMBEC, SYFPEITHI, and Rankpep) was applied to identify high-affinity 9-mer epitopes from the CCHFV Gc protein restricted by human HLA-I and murine H2 alleles. Immunogenicity, conservation, toxicity, and allergenicity were assessed using established computational tools. Peptide–MHC interactions were further examined by molecular docking and molecular dynamics simulations. Selected epitopes were experimentally validated by ELISpot assays in BALB/c and SJL mice immunized with a Gc-based DNA vaccine. Results: Ninety-four human HLA-I and thirty-seven murine H2-restricted dominant epitopes were predicted. Among these, 21 epitopes exhibited high binding affinity, favorable immunogenicity, and broad conservation across viral strains. Most candidates showed low predicted toxicity and allergenicity. Structural analyses supported stable peptide–MHC interactions. ELISpot assays confirmed that several epitopes, including APFILLILF and FVKWKVEYI, elicited significant IL-2 responses, indicating functional T-cell activation. Conclusion: This study provides a systematic framework for identifying conserved and immunogenic pan-MHC-I-restricted epitopes within the CCHFV Gc protein. The validated candidates may support the rational design of multi-epitope vaccines and contribute to understanding cellular immune responses against CCHFV.
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1693892
Open AccessImmunoreactivity of pan MHC-I epitopes on Crimean-Congo hemorrhagic fever virus glycoprotein C-terminal
Introduction: Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne pathogen causing severe hemorrhagic disease with high mortality. The viral glycoprotein Gc mediates membrane fusion and represents a key target of CD8⁺ T-cell responses. However, systematic identification and comprehensive evaluation of pan-MHC-I-restricted Gc epitopes remain limited. Methods: An integrated immunoinformatics workflow incorporating five prediction algorithms (IEDB, NetMHCpan4.1, SMMPMBEC, SYFPEITHI, and Rankpep) was applied to identify high-affinity 9-mer epitopes from the CCHFV Gc protein restricted by human HLA-I and murine H2 alleles. Immunogenicity, conservation, toxicity, and allergenicity were assessed using established computational tools. Peptide–MHC interactions were further examined by molecular docking and molecular dynamics simulations. Selected epitopes were experimentally validated by ELISpot assays in BALB/c and SJL mice immunized with a Gc-based DNA vaccine. Results: Ninety-four human HLA-I and thirty-seven murine H2-restricted dominant epitopes were predicted. Among these, 21 epitopes exhibited high binding affinity, favorable immunogenicity, and broad conservation across viral strains. Most candidates showed low predicted toxicity and allergenicity. Structural analyses supported stable peptide–MHC interactions. ELISpot assays confirmed that several epitopes, including APFILLILF and FVKWKVEYI, elicited significant IL-2 responses, indicating functional T-cell activation. Conclusion: This study provides a systematic framework for identifying conserved and immunogenic pan-MHC-I-restricted epitopes within the CCHFV Gc protein. The validated candidates may support the rational design of multi-epitope vaccines and contribute to understanding cellular immune responses against CCHFV.
- 4 December 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 795, 153081
Direct targeting of the nucleocapsid protein by morin inhibits Hantaan virus infection
- 4 December 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 795, 153081
Direct targeting of the nucleocapsid protein by morin inhibits Hantaan virus infection
- 17 May 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 158, 114865
Comparative immunobiology and cross-species validations of pan-MHC-II epitopes on Hantaan virus nucleocapsid protein
- 17 May 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 158, 114865
Comparative immunobiology and cross-species validations of pan-MHC-II epitopes on Hantaan virus nucleocapsid protein
- Open Access
- 23 October 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-15
A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus
Hemorrhagic fever with renal syndrome (HFRS) occurs throughout Eurasia with considerable morbidity and mortality. Currently, the absence of specific treatments or effective antiviral drugs for hantavirus infection makes developing safe and effective vaccines a high priority. Here, we report the development of three novel nucleic acid vaccine candidates, mRNA, naked DNA, and DNA encapsulated in lipid nanoparticles, encoding the glycoproteins of the Hantaan virus (HTNV). To comprehensively evaluate the potential of candidate HTNV nucleic acid vaccines in preventing HFRS, we focus on evaluating their immunogenicity and efficacy in mice and comparing them with an inactivated vaccine as the benchmark. Our findings reveal that all candidate vaccines activated instant and sustained immune responses, offering comparable in vivo protective efficacy to the inactivated vaccines. Notably, compared to the inactivated vaccine, mRNA vaccine induced stronger virus-specific T-helper 1 cell immune response, while DNA-LNP elicited higher levels of neutralizing antibodies in mice. These results mark a significant step in developing nucleic acid vaccines for HTNV, suggesting that sequential immunization with DNA and mRNA vaccines could further amplify the advantages of nucleic acid vaccines.
- 23 October 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-15
Open AccessA comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus
Hemorrhagic fever with renal syndrome (HFRS) occurs throughout Eurasia with considerable morbidity and mortality. Currently, the absence of specific treatments or effective antiviral drugs for hantavirus infection makes developing safe and effective vaccines a high priority. Here, we report the development of three novel nucleic acid vaccine candidates, mRNA, naked DNA, and DNA encapsulated in lipid nanoparticles, encoding the glycoproteins of the Hantaan virus (HTNV). To comprehensively evaluate the potential of candidate HTNV nucleic acid vaccines in preventing HFRS, we focus on evaluating their immunogenicity and efficacy in mice and comparing them with an inactivated vaccine as the benchmark. Our findings reveal that all candidate vaccines activated instant and sustained immune responses, offering comparable in vivo protective efficacy to the inactivated vaccines. Notably, compared to the inactivated vaccine, mRNA vaccine induced stronger virus-specific T-helper 1 cell immune response, while DNA-LNP elicited higher levels of neutralizing antibodies in mice. These results mark a significant step in developing nucleic acid vaccines for HTNV, suggesting that sequential immunization with DNA and mRNA vaccines could further amplify the advantages of nucleic acid vaccines.
- Open Access
DNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection
Vaccines has long been the focus of antiviral immunotherapy research. Viral epitopes are thought to be useful biomarkers for immunotherapy (both antibody-based and cellular). In this study, we designed a novel vaccine molecule, the Hantaan virus (HTNV) glycoprotein (GP) tandem Th epitope molecule (named the Gnc molecule), in silico. Subsequently, computer analysis was used to conduct a comprehensive and in-depth study of the various properties of the molecule and its effects as a vaccine molecule in the body. The Gnc molecule was designed for DNA vaccines and optimized with a lysosomal-targeting membrane protein (LAMP) strategy. The effects of GP-derived Th epitopes and multiepitope vaccines were initially verified in animals. Our research has resulted in the design of two vaccines based on effective antiviral immune targets. The effectiveness of molecular therapies has also been preliminarily demonstrated in silico and in laboratory animals, which lays a foundation for the application of a vaccines strategy in the field of antivirals.
Open AccessDNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection
Vaccines has long been the focus of antiviral immunotherapy research. Viral epitopes are thought to be useful biomarkers for immunotherapy (both antibody-based and cellular). In this study, we designed a novel vaccine molecule, the Hantaan virus (HTNV) glycoprotein (GP) tandem Th epitope molecule (named the Gnc molecule), in silico. Subsequently, computer analysis was used to conduct a comprehensive and in-depth study of the various properties of the molecule and its effects as a vaccine molecule in the body. The Gnc molecule was designed for DNA vaccines and optimized with a lysosomal-targeting membrane protein (LAMP) strategy. The effects of GP-derived Th epitopes and multiepitope vaccines were initially verified in animals. Our research has resulted in the design of two vaccines based on effective antiviral immune targets. The effectiveness of molecular therapies has also been preliminarily demonstrated in silico and in laboratory animals, which lays a foundation for the application of a vaccines strategy in the field of antivirals.
- 1 August 2024
- Vol. 40 (8) , 761-766
[Exploring a novel instructional paradigm for the Fundamentals of Immunity and Infection module in our university: A study based on the O-PIRTAS flipped classroom approach].
Medical Microbiology and Medical Immunology are important components of our university's the modular teaching on fundamentals of immunity and infection. Among these, Bacterial Infection and Immunity serves as a bridge between Medical Microbiology and Medical Immunology. This chapter mainly introduces how pathogenic bacteria invade the body to cause infection and how the body's immune system resists bacterial infection. Studying this chapter, students can build a framework knowledge on infection-immunity. However, due to the complexity of the content and the limited duration of the course, the traditional teaching method struggles to help students clarify the knowledge structure, resulting in poor learning outcomes. Therefore, there is an urgent need for reforms. Using the bacterial infection and immunity chapter as an example, this article explores the teaching reform of the Fundamentals of Immunology and Infection module based on the O-PIRTAS flipped classroom model, providing valuable insights for subsequent teaching reforms.
- 1 August 2024
- Vol. 40 (8) , 761-766
[Exploring a novel instructional paradigm for the Fundamentals of Immunity and Infection module in our university: A study based on the O-PIRTAS flipped classroom approach].
Medical Microbiology and Medical Immunology are important components of our university's the modular teaching on fundamentals of immunity and infection. Among these, Bacterial Infection and Immunity serves as a bridge between Medical Microbiology and Medical Immunology. This chapter mainly introduces how pathogenic bacteria invade the body to cause infection and how the body's immune system resists bacterial infection. Studying this chapter, students can build a framework knowledge on infection-immunity. However, due to the complexity of the content and the limited duration of the course, the traditional teaching method struggles to help students clarify the knowledge structure, resulting in poor learning outcomes. Therefore, there is an urgent need for reforms. Using the bacterial infection and immunity chapter as an example, this article explores the teaching reform of the Fundamentals of Immunology and Infection module based on the O-PIRTAS flipped classroom model, providing valuable insights for subsequent teaching reforms.
- 6 December 2023
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 55 (1) , 125-132
Genomic sequencing revealed recombination event between clade 1 and clade 2 occurs in circulating varicella-zoster virus in China
Varicella-zoster virus (VZV), a member of the Alphaherpesvirinae subfamily, causes varicella in primary infections and establishing a latent stage in sensory ganglia. Upon reactivation, VZV causes herpes zoster with severe neuralgia, especially in elderly patients. The mutation rate for VZV is comparatively lower than the other members of other alpha herpesviruses. Due to geographic isolation, different genotypes of VZV are circulating on separate continents. Here, we successfully isolated a VZV from the vesicular fluid of a youth zoster patient. Based on the single-nucleotide polymorphism profiles of different open reading frames that define the genotype, this newly isolated VZV primarily represents genotype clade 2 but also has characteristics of genotype clade 1. The next-generation sequencing provided a nearly full-length sequence, and further phylogenetic analysis revealed that this VZV isolate is distinct from clades 1 and 2. The Recombination Detection Program indicates that a possible recombinant event may occur between the VZV isolate and clade 1. In summary, we found that there is a circulating VZV isolate in China that may represent a recombinant between clade 1 and clade 2, providing new concerns that need to be considered in the future VZV vaccination program.
- 6 December 2023
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 55 (1) , 125-132
Genomic sequencing revealed recombination event between clade 1 and clade 2 occurs in circulating varicella-zoster virus in China
Varicella-zoster virus (VZV), a member of the Alphaherpesvirinae subfamily, causes varicella in primary infections and establishing a latent stage in sensory ganglia. Upon reactivation, VZV causes herpes zoster with severe neuralgia, especially in elderly patients. The mutation rate for VZV is comparatively lower than the other members of other alpha herpesviruses. Due to geographic isolation, different genotypes of VZV are circulating on separate continents. Here, we successfully isolated a VZV from the vesicular fluid of a youth zoster patient. Based on the single-nucleotide polymorphism profiles of different open reading frames that define the genotype, this newly isolated VZV primarily represents genotype clade 2 but also has characteristics of genotype clade 1. The next-generation sequencing provided a nearly full-length sequence, and further phylogenetic analysis revealed that this VZV isolate is distinct from clades 1 and 2. The Recombination Detection Program indicates that a possible recombinant event may occur between the VZV isolate and clade 1. In summary, we found that there is a circulating VZV isolate in China that may represent a recombinant between clade 1 and clade 2, providing new concerns that need to be considered in the future VZV vaccination program.
- Open Access
- 21 March 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1121163
Construction and evaluation of DNA vaccine encoding Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1
Crimean-Congo hemorrhagic fever virus (CCHFV) can cause severe hemorrhagic fever in humans and is mainly transmitted by ticks. There is no effective vaccine for Crimean-Congo hemorrhagic fever (CCHF) at present. We developed three DNA vaccines encoding CCHFV nucleocapsid protein (NP), glycoprotein N-terminal (Gn) and C-terminal (Gc) fused with lysosome-associated membrane protein 1 (LAMP1) and assessed their immunogenicity and protective efficacy in a human MHC (HLA-A11/DR1) transgenic mouse model. The mice that were vaccinated three times with pVAX-LAMP1-CCHFV-NP induced balanced Th1 and Th2 responses and could most effectively protect mice from CCHFV transcription and entry-competent virus-like particles (tecVLPs) infection. The mice vaccinated with pVAX-LAMP1-CCHFV-Gc mainly elicited specific anti-Gc and neutralizing antibodies and provided a certain protection from CCHFV tecVLPs infection, but the protective efficacy was less than that of pVAX-LAMP1-CCHFV-NP. The mice vaccinated with pVAX-LAMP1-CCHFV-Gn only elicited specific anti-Gn antibodies and could not provide sufficient protection from CCHFV tecVLPs infection. These results suggest that pVAX-LAMP1-CCHFV-NP would be a potential and powerful candidate vaccine for CCHFV.
- 21 March 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1121163
Open AccessConstruction and evaluation of DNA vaccine encoding Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1
Crimean-Congo hemorrhagic fever virus (CCHFV) can cause severe hemorrhagic fever in humans and is mainly transmitted by ticks. There is no effective vaccine for Crimean-Congo hemorrhagic fever (CCHF) at present. We developed three DNA vaccines encoding CCHFV nucleocapsid protein (NP), glycoprotein N-terminal (Gn) and C-terminal (Gc) fused with lysosome-associated membrane protein 1 (LAMP1) and assessed their immunogenicity and protective efficacy in a human MHC (HLA-A11/DR1) transgenic mouse model. The mice that were vaccinated three times with pVAX-LAMP1-CCHFV-NP induced balanced Th1 and Th2 responses and could most effectively protect mice from CCHFV transcription and entry-competent virus-like particles (tecVLPs) infection. The mice vaccinated with pVAX-LAMP1-CCHFV-Gc mainly elicited specific anti-Gc and neutralizing antibodies and provided a certain protection from CCHFV tecVLPs infection, but the protective efficacy was less than that of pVAX-LAMP1-CCHFV-NP. The mice vaccinated with pVAX-LAMP1-CCHFV-Gn only elicited specific anti-Gn antibodies and could not provide sufficient protection from CCHFV tecVLPs infection. These results suggest that pVAX-LAMP1-CCHFV-NP would be a potential and powerful candidate vaccine for CCHFV.
- Open Access
- 19 July 2021
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 11, 671694
Integrative Analysis of HTNV Glycoprotein Derived MHC II Epitopes by In Silico Prediction and Experimental Validation
Hantaan virus (HTNV), the causative pathogen of hemorrhagic fever with renal syndrome (HFRS), is a negative RNA virus belonging to the Orthohantaviridae family. HTNV envelope glycoprotein (GP), encoded by the genomic medium segment, is immunogenic and is therefore a promising vaccine candidate. Major histocompatibility complex class I (MHC-I) epitopes derived from HTNV has been extensively studied, but little is known of MHC-II epitopes. In silico predictions based on four databases indicated that the full-length HTNV GP has 1121 15-mer epitopes, of which 289 had a high score for binding to the human and murine MHC-II superfamily. It found that epitope ILTVLKFIANIFHTS could potentially bind most MHC-II molecules covering human and murine haplotypes. Dominant epitopes were validated by enzyme-linked immunospot assay of splenocytes from immunized mice; 6 of 10 epitopes supported the predictions including TATYSIVGPANAKVP, TKTLVIGQCIYTITS, FSLLPGVAHSIAVEL, CETYKELKAHGVSCP, CGLYLDRLKPVGSAY, and NLGENPCKIGLQTSS. Conservation analysis of dominant epitopes revealed host–virus interactions without geographic stratification, thus meeting the requirements of candidate vaccines for large-population prophylaxis. These findings provide insight into hantavirus antigenicity and suggest that vaccines targeting MHC-II could provide immune protection in large population to complement symptomatic therapies for the treatment of HFRS.
- 19 July 2021
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 11, 671694
Open AccessIntegrative Analysis of HTNV Glycoprotein Derived MHC II Epitopes by In Silico Prediction and Experimental Validation
Hantaan virus (HTNV), the causative pathogen of hemorrhagic fever with renal syndrome (HFRS), is a negative RNA virus belonging to the Orthohantaviridae family. HTNV envelope glycoprotein (GP), encoded by the genomic medium segment, is immunogenic and is therefore a promising vaccine candidate. Major histocompatibility complex class I (MHC-I) epitopes derived from HTNV has been extensively studied, but little is known of MHC-II epitopes. In silico predictions based on four databases indicated that the full-length HTNV GP has 1121 15-mer epitopes, of which 289 had a high score for binding to the human and murine MHC-II superfamily. It found that epitope ILTVLKFIANIFHTS could potentially bind most MHC-II molecules covering human and murine haplotypes. Dominant epitopes were validated by enzyme-linked immunospot assay of splenocytes from immunized mice; 6 of 10 epitopes supported the predictions including TATYSIVGPANAKVP, TKTLVIGQCIYTITS, FSLLPGVAHSIAVEL, CETYKELKAHGVSCP, CGLYLDRLKPVGSAY, and NLGENPCKIGLQTSS. Conservation analysis of dominant epitopes revealed host–virus interactions without geographic stratification, thus meeting the requirements of candidate vaccines for large-population prophylaxis. These findings provide insight into hantavirus antigenicity and suggest that vaccines targeting MHC-II could provide immune protection in large population to complement symptomatic therapies for the treatment of HFRS.